OCS
Oculis Holding Ag
NASDAQ · Pharmaceuticals
$28.48
+0.99 (+3.60%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 335.81M | 321.14M | 281.93M |
| Net Income | 75.81M | 72.36M | 63.56M |
| EPS | — | — | — |
| Profit Margin | 22.6% | 22.5% | 22.5% |
| Rev Growth | +1.2% | -6.4% | +18.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 316.00M | 325.49M | 320.75M |
| Total Equity | 562.30M | 501.72M | 538.47M |
| D/E Ratio | 0.56 | 0.65 | 0.60 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 137.16M | 117.64M | 104.92M |
| Free Cash Flow | 80.35M | 48.21M | 59.98M |